A central focus of our group is the development and application of advanced experimental skin models. We use three-dimensional (3D) skin equivalent cultures and other in vitro systems to study skin biology, disease mechanisms, and therapeutic strategies in a controlled environment. These models allow us to investigate epidermal barrier function, tissue regeneration, inflammation, and interactions between skin cells and the immune system.
We investigate the molecular and cellular mechanisms underlying epidermolysis bullosa (EB), a group of inherited blistering disorders characterized by skin fragility and chronic wounds. Using patient-derived and engineered experimental models, we study disease pathogenesis and evaluate innovative therapeutic approaches aimed at improving skin stability and patient quality of life. Our work bridges fundamental discoveries and translational research to accelerate the development of future treatments.
Our research addresses the pathomechanisms of autoimmune blistering diseases, including the interactions between autoantibodies, skin cells, and the immune system that drive blister formation. By studying disease-specific immune responses and tissue alterations, we aim to identify novel therapeutic targets and improve disease management.
The group develops and validates in-house diagnostic assays for autoimmune blistering diseases. These diagnostic platforms support accurate disease classification, enable improved patient care, and facilitate research into disease mechanisms and treatment responses. Our diagnostic expertise closely integrates clinical care with laboratory-based investigations.
Effective treatment of skin diseases requires efficient and selective delivery of therapeutics to affected tissues. We develop and evaluate novel strategies for targeted drug delivery to the skin, aiming to increase therapeutic efficacy while minimizing systemic exposure and side effects. Experimental models are used to optimize drug penetration, delivery systems, and treatment outcomes.
Skin diseases affect millions of individuals worldwide and can substantially reduce quality of life. Our research contributes to improved diagnosis, understanding, and treatment of both rare and common skin disorders. By developing advanced experimental models, innovative diagnostic tools, and targeted therapeutic approaches, we support precision medicine in dermatology and help translate laboratory discoveries into clinical applications. Particular emphasis is placed on improving outcomes for patients with epidermolysis bullosa and autoimmune blistering diseases, conditions that currently have significant unmet medical needs.
Experimental Dermatology, Department of Dermatology
University Medical Center Groningen
Internal postcode AB21
PO BOX 30.001
9700 RB Groningen
The Netherlands
Experimental Dermatology, Department of Dermatology
University Medical Center Groningen
Hanzeplein 1
9713 GZ Groningen
The Netherlands
